Hostname: page-component-7b9c58cd5d-hxdxx Total loading time: 0 Render date: 2025-03-15T16:26:38.409Z Has data issue: false hasContentIssue false

Fetal programming by androgen excess impairs liver lipid content and PPARg expression in adult rats

Published online by Cambridge University Press:  19 July 2021

Aimé Florencia Silva*
Affiliation:
Laboratorio de Fisiopatología Ovárica, Centro de Estudios Farmacológicos y Botánicos (CEFyBO), Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, CP1121, Ciudad Autónoma de Buenos Aires, Argentina
Giselle Adriana Abruzzese
Affiliation:
Laboratorio de Fisiopatología Ovárica, Centro de Estudios Farmacológicos y Botánicos (CEFyBO), Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, CP1121, Ciudad Autónoma de Buenos Aires, Argentina
María José Ferrer
Affiliation:
Laboratorio de Fisiopatología Ovárica, Centro de Estudios Farmacológicos y Botánicos (CEFyBO), Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, CP1121, Ciudad Autónoma de Buenos Aires, Argentina
María Florencia Heber
Affiliation:
Laboratorio de Fisiopatología Ovárica, Centro de Estudios Farmacológicos y Botánicos (CEFyBO), Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, CP1121, Ciudad Autónoma de Buenos Aires, Argentina
Silvana Rocío Ferreira
Affiliation:
Laboratorio de Fisiopatología Ovárica, Centro de Estudios Farmacológicos y Botánicos (CEFyBO), Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, CP1121, Ciudad Autónoma de Buenos Aires, Argentina
Gloria Edith Cerrone
Affiliation:
Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología, Biotecnología y Genética, Cátedra de Genética, Junín 954, C1113 AAD, Ciudad Autónoma de Buenos Aires, Argentina
Alicia Beatriz Motta
Affiliation:
Laboratorio de Fisiopatología Ovárica, Centro de Estudios Farmacológicos y Botánicos (CEFyBO), Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, CP1121, Ciudad Autónoma de Buenos Aires, Argentina
*
Address for correspondence: Aimé Florencia Silva, Center of Pharmacological and Botanical Studies, School of Medicine, University of Buenos Aires, Paraguay 2155, 17th Floor, CP1121, Buenos Aires, Argentina. Email: aime.095@hotmail.com
Rights & Permissions [Opens in a new window]

Abstract

It is known that prenatal hyperandrogenization induces alterations since early stages of life, contributing to the development of polycystic ovary syndrome affecting the reproductive axis and the metabolic status, thus promoting others associated disorders, such as dyslipidemia, insulin resistance, liver dysfunction, and even steatosis. In this study, we aimed to evaluate the effect of fetal programming by androgen excess on the hepatic lipid content and metabolic mediators at adult life. Pregnant rats were hyperandrogenized with daily subcutaneous injections of 1 mg of free testosterone from days 16 to 19 of pregnancy. The prenatally hyperandrogenized (PH) female offspring displayed two phenotypes: irregular ovulatory phenotype (PHiov) and anovulatory phenotype (PHanov), with different metabolic and endocrine features. We evaluated the liver lipid content and the main aspect of the balance between fatty acid (FA) synthesis and oxidation. We investigated the status of the peroxisomal proliferator-activated receptors (PPARs) alpha and gamma, which act as lipid mediators, and the adipokine chemerin, one marker of liver alterations. We found that prenatal hyperandrogenization altered the liver lipid profile with increased FAs levels in the PHanov phenotype and decreased cholesterol content in the PHiov phenotype. FA metabolism was also disturbed, including decreased mRNA and protein PPARgamma levels and impaired gene expression of the main enzymes involved in lipid metabolism. Moreover, we found low chemerin protein levels in both PH phenotypes. In conclusion, these data suggest that prenatal hyperandrogenization exerts a negative effect on the liver and alters lipid content and metabolic mediators’ expression at adult age.

Type
Original Article
Copyright
© The Author(s), 2021. Published by Cambridge University Press in association with International Society for Developmental Origins of Health and Disease

Introduction

Fetal programming is a complex phenomenon in which different insults could lead to adaptive processes that negatively affect fetal development. When hostile factors disrupt the intrauterine environment, the development of the gestational organism could be altered and, consequently, generate future health problems in the offspring. Reference Marciniak, Patro-Małysza and Kimber-Trojnar1 Although the exact mechanisms of fetal programming are not entirely understood, this phenomenon induces gene expression changes, involving epigenetic alterations, and thereby modifies tissue functions and, in some cases, predisposes to adult-onset diseases. Reference Saffery and Novakovic2

The liver is a crucial organ in metabolic regulation that controls the body energy balance. Reference Trefts, Gannon and Wasserman3 It is responsible for glucose and insulin metabolism, energy storage, and lipid availability, Reference Paschos and Paletas4 and alterations in any of these pathways may lead to liver diseases. Reference Kawano and Cohen5 In particular, it has been suggested that androgen excess contributes to hepatic dysfunctions. In the liver, this steroid hormone may act in a direct manner by the androgen receptor signaling, Reference Ma, Lai and Yeh6 and indirectly by both the modulation of insulin pathways Reference Marchesini, Brizi and Morselli-Labate7 and the increased visceral adiposity, Reference Diamanti-Kandarakis and Dunaif8 or by a combination of these three actions. In this regard, some studies have reported that fetal programming by androgen excess affects fetal liver functions, leads to metabolic disorders, and deregulates lipid metabolism in adult offsprings.9,Reference Vassilatou10 However, the exact mechanisms by which androgen excess is able to program liver functions remain unknown.

The liver plays a major role in lipid metabolism and energy homeostasis, and it may produce energy using carbohydrates and triglycerides (TG). Reference Trefts, Gannon and Wasserman3 Alterations in hepatic lipid metabolism affect not only metabolic homeostasis but also the immune response. Reference Trefts, Gannon and Wasserman3 Under physiological conditions, there is a balance in the liver between the import and export of fatty acids (FAs) and lipid metabolism. When this balance is altered, liver accumulation of lipid droplets can occur, leading to steatosis (TG accumulation in hepatocytes), and even non-alcoholic fatty liver disease (NAFLD). Reference Kawano and Cohen5,Reference Browning and Horton11

Lipid pathways are mainly controlled at the transcriptional level by multiple master regulators. Reference Browning and Horton11,Reference Nguyen, Leray and Diez12 Particularly, the peroxisomal proliferator-activated receptors (PPARs) are a family of nuclear receptors, which present three isoforms: alpha (PPARa), beta/delta (PPARb/d), and gamma (PPARg), encoded by different genes with differential functions. They are involved in the gene regulation of multiple metabolic pathways, such as lipid metabolism, glucose and insulin homeostasis, and inflammatory processes, among others. Reference Smith13,Reference Tyagi, Gupta and Saini14 Regarding PPARa, it plays a crucial role in FA oxidation, Reference Pawlak, Lefebvre and Staels15 while PPARg participates in the synthesis and storage of FA. Reference Ables16 Moreover, it has been described that several signaling molecules involved in lipid and energy metabolism, including adipokines, may be regulated by PPARg. Reference Muruganandan, Parlee and Rourke17

The adipokines are polypeptides produced mainly, but not exclusively, by adipose tissue. They are involved in several processes, such as the regulation of insulin and glucose metabolism and inflammatory state. Reference Boutari, Perakakis and Mantzoros18 It has been reported that adipokines influence lipid metabolism in several target tissues. Reference Lago, Gómez and Gómez-Reino19 In this context, adipokines alterations contribute to the development of lipid disorders. Reference Polyzos, Kountouras and Mantzoros20 One of these adipokines is chemerin, which is mainly synthesized by the liver and adipose tissue. Reference Bozaoglu, Bolton and McMillan21 It has been associated with some pathologies, such as obesity, NAFLD, metabolic syndrome, and polycystic ovary syndrome (PCOS). Reference Ademoglu, Berberoglu and Carlioglu22,Reference Ferland and Watts23 Moreover, it has been described that chemerin promotes adipogenesis and regulates immunity as well as glucose metabolism. Reference Bondue, Wittamer and Parmentier24,Reference Helfer and Wu25 Additionally, a sequence analysis revealed a PPARg response element within the chemerin promoter, Reference Muruganandan, Parlee and Rourke17 suggesting that this transcriptional factor regulates its expression.

We have previously demonstrated that fetal programming generated by prenatal androgen excess induces systemic insulin and glucose metabolism alterations at adulthood (90 days of age) in both prenatally hyperandrogenized (PH) phenotypes. Reference Abruzzese, Heber and Ferrer26 Besides, we have demonstrated the presence of insulin and glucose signaling disruption and a pro-oxidant state in the liver, although there was no evidence of TG accumulation. Reference Abruzzese, Heber and Ferrer26 Additionally, impaired hepatic lipogenesis was found at puberty (60 days of life) in the absence of obesity, Reference Abruzzese, Heber and Ferreira27 but it is known that the consequences of fetal programming on the affected organism could change over time. Reference Heber, Ferreira and Vélez28,Reference Padmanabhan, Salvetti and Matiller29 Thereby, in the present study, we aimed to deepen the impact of prenatal hyperandrogenization in hepatic lipid metabolism during adulthood, focusing on lipid content, lipogenesis, and the main regulators of beta-oxidation (b-oxidation). In addition, we were interested in characterizing the effects of fetal androgen exposure on hepatic chemerin expression, a poorly understood adipokine.

Materials and methods

Animals and experimental designs

Virgin female rats of Sprague Dawley strain were mated with fertile males of the same strain. Three females and one male were housed in each cage under controlled conditions of light (12h light:12h darkness cycle) and temperature (23°C–25°C). Animals received food and water ad libitum. Day 0 of pregnancy was defined as the morning on which spermatozoa were observed in the vaginal fluid. Between days 16 and 19 of pregnancy, one group of rats was hyperandrogenized, as described before. Reference Abruzzese, Heber and Ferreira27,Reference Demissie, Lazic and Foecking30 Pregnant rats (N = 10) received daily subcutaneous injections of 1 mg free testosterone (T-1500; Sigma) dissolved in 100 µl sesame oil. The testosterone administered mimics the fetal testosterone surge observed in male rats when the reproductive axis in the fetus is established. Reference Wolf, Hotchkiss and Ostby31 Another group (N = 10) received only 100 µl of sesame oil. Under the conditions of our animal facilities, spontaneous term labor occurs on day 22 of gestation. Pups were culled from litters to equalize group sizes (8 pups per mother). Female offspring were separated from males at 21 days of age and randomly chosen. Those from hyperandrogenized mothers formed the PH group, and the offspring from mothers who received the vehicle only formed the Control group. Animals were allowed free access to Purina rat chow (Cooperación SRL, Argentina) and water. All the procedures involving animals were conducted in accordance with the Animal Care and Use Committee of Consejo Nacional de Investigaciones Científicas y Tecnicas (CONICET) 1996, Argentina, and the study was approved by the Ethics Committee of the School of Medicine of University of Buenos Aires. The estrous cycle was determined by vaginal smears taken daily from 70 to 90 days of age. The Control animals had regular ovulatory cycles (100 %), presenting smears displaying the four stages of the estrous cycle in the following order: proestrus, estrus, metaestrus, diestrus, with cycles of 4–6 days. Reference Heber, Ferreira and Abruzzese32 The PH group showed two phenotypes: (i) irregular ovulatory phenotype (PHiov) (49%–50%), in which the animals showed some smears not following the progress of the cycle as described above, or whose cycles lasted 7 days or more; (ii) anovulatory phenotype (PHanov) (38%–43 %), with animals whose smears showed metaestrus, diestrus, or a combination of both for four consecutive days, and were thus considered to be non-cycling. Reference Heber, Ferreira and Abruzzese32 Animals from the Control, PHiov, and PHanov groups showed no significant differences in body weight (231 ± 15, 238 ± 22, and 231 ± 19 g, respectively). Reference Abruzzese, Heber and Ferrer26 As we previously reported, serum testosterone levels were increased in the PHanov group as compared to the PHiov and Control groups (Control = 67.76 ± 13.52 pg/ml; PHiov = 115.84 ± 34.82 pg/ml; and PHanov = 154.34 ± 32.00 pg/ml). Reference Heber, Ferreira and Abruzzese32 Moreover, serum estradiol levels were lower for both PH groups as compared to the Control group (Control =12.25 ± 2.31 pg/ml; PHiov = 9.69 ± 1.93 pg/ml; and PHanov =8.05 ± 1.24 pg/ml), Reference Heber, Ferreira and Abruzzese32 and the estradiol-to-testosterone ratio was also decreased in both PH phenotypes, showing that the PH groups present a hormonal imbalance.

At 90 days of age, female offspring from each group were anesthetized with carbon dioxide and killed by decapitation. As the PHanov group remained in diestrus, all animals were euthanized at this stage, to allow the comparison between phenotypes. The liver was separated and conserved at −80°C for further studies. All animals were randomly assigned to each assay considering the littermate. Thus, each assay was carried out with the same number of PHiov and PHanov animals from each randomly selected littermate.

Liver lipid content

To evaluate the TG content in the liver, six frozen samples of each group were saponified and the TG content was quantified by comparing it with a glycerol standard curve using a commercial kit (Wiener Lab, Argentina), as previously described. Reference Chow, Jones and Prelle33 The results are expressed as mg of TG/g tissue.

To analyze the FA, cholesterol, and cholesterol ester content, a lipid extraction was performed from six hepatic samples per group according to Blight and Dyer method. Reference Bligh and Dyer34 Briefly, hepatic tissue was homogenized in 1 ml of phosphate-buffered saline (PBS), and protein content in the homogenates was measured by Bradford assay. Reference Bradford35 Tissue lipids were extracted from 500 µl of each homogenate by three rounds of organic extraction in methanol:chloroform (2:1), as previously performed. Reference Fornes, White and Higa36 The lipids extracted were developed by thin layer chromatography in 0.2 mm silica gel plates (Merck, Darmstadt, Germany). Along with the samples of each group, a known standard solution was developed. The plates were placed in a running buffer (hexane: ether: acetic acid [80:20:2, v:v:v] as the developing solvent mixture) for 30–45 min to allow polarity separation of the different lipid species. They were stained with iodine vapors and the plate was scanned. Densitometric analysis of the area intensity of each spot was performed with the Image J software. Quantification was performed by extrapolation from the standard curves built with the densitometric values of standards run in the same plate. The results are expressed as µg of lipid species/mg protein.

Liver lipid metabolism

Gene expression

The mRNA levels of Ppara and Pparg, PPAR co-activator 1a (Pgc1a), acetyl-CoA carboxylase (ACC) 1 and 2 (Acaca and Acacb, respectively), fatty acid synthase (Fas), stearoyl-CoA desaturase (Scd1), adipose triglyceride lipase (Atgl), carnitine palmitoyltransferase 1 (Cpt1), and Chemerin were evaluated by real-time polymerase chain reaction (real-time PCR) analysis. Total mRNA from hepatic tissue (six samples per group) was extracted using RNAzol RT (MRC gene, Molecular Research Center, Cincinnati, OH, USA) following the manufacturer’s instructions. cDNA was synthesized from 500 ng mRNA using random primers. This cDNA (2.5 μl) was used for real-time PCR analysis in 10 μl reaction buffer containing a 20 mM dNTPs mix, MgCl2, GoTaq Polymerase (Promega), Eva Green 20x (Biotium Hayward, CA, USA), and gene-specific primers in a total volume of 12.5 μl. The qPCR conditions started with a denaturation step at 95°C for 4 min and followed by up to 50 cycles of denaturation (95 °C, for 20 s), annealing (see temperature for each primer in Table 1, for 25 s), and primer extension (72 °C, for 25 s). The amplified products were quantified by fluorescence using the Rotor Gene 6000 Corbett, and mRNA abundance was normalized to the 60s ribosomal protein L32 (L32) amount. L32 was validated as a reference gene because the variance between treatments did not differ. Gene expression was quantified using the 2–ΔΔCt method. Reference Livak and Schmittgen37 The results are expressed as arbitrary units. The primers are given in Table 1.

Table 1. List of primers used in real-time PCR

F, forward sequence; R, reverse sequence.

Protein expression

The hepatic protein levels of PPARa, PPARg, and CHEMERIN were analyzed by Western Blot, as previously described. Reference Abruzzese, Heber and Ferrer26 Briefly, 100 mg of liver tissue (six samples per group) was lysed at 4 °C in 500 μl lysis buffer (20 mM Tris-HCl, pH = 8.0, 137 mM NaCl, 1% Nonidet P-40 and 10% glycerol) and supplemented with protease inhibitors (Protease Inhibitor Cocktail P8340, Sigma Aldrich, St. Louis MO, USA). The lysate was centrifuged at 4 °C for 10 min at 10,000 g and the pellet was discarded. Protein concentrations in the supernatant were measured by the Bradford assay (Bio-Rad). Reference Bradford35 Total proteins (50 μg) were denatured and separated on a sodium dodecyl sulfate (SDS-polyacrylamide gel (12%) and transferred onto nitrocellulose membranes (GE Healthcare, Life Sciences). Membranes were blocked for 1 h at room temperature in 5% (w/v) nonfat dry milk in PBS and then incubated at 4 °C overnight with the primary antibody. Anti-PPARg 1 + 2 1:1000 (ab41928, Abcam, Cambridge, UK), anti-PPARa 1:400 (15540-1-AP, PROTEINTECH), and anti-CHEMERIN 1:800 (ab112540, Abcam) were used as primary antibodies. The membranes were washed three times for 7 min each in Tris buffered saline with Tween (TBST) (4 mM Tris-HCl, pH = 7.5, 100 mM NaCl, 0.1% Tween 20). Then, they were incubated at room temperature for 1 h with the secondary antibody, species-specific antirabbit and antimouse IgG (according to the primary antibody), linked to horse recombinant peroxidase (1: 3000, 1,706,515, BioRad or 1: 5000, ab6728, Abcam, respectively) while being rocked. After three washings of 7 min each with TBST, the band intensities were quantified by an image analyzed (GeneGnome XRQ, Syngene Synoptics Group, Cambridge, UK). The intensity of bands was analyzed using the Image J program and normalized relative to total protein relation, since tubulin protein levels changed in response to the experimental treatment. Reference Araujo, Bordin and Carvalho38,Reference Rein-Fischboeck, Pohl and Haberl39 Staining of the total protein on the blotting membrane has emerged as a better loading control than housekeeping proteins, since multiple advantages have been described: smaller technical and biological variations, unlikely signal saturation, no collision between the protein of interest and loading control signal, improvement of the sensitivity and accuracy of Western Blot results, among others. Reference Moritz40Reference Nie, Li and Hu42 Using the total protein method, a range between the certain protein weight was analyzed. The results are expressed as arbitrary units.

Statistical analysis

Statistical analyses were carried out using InfoStat program Reference Di Rienzo, Casanoves and Balzarini43 and GraphPad Instat® software (GraphPad Software, San Diego, CA, USA). ANOVA with post hoc Tukey test was used to compare the three phenotypes. The normality of data (Shapiro–Wilks test) and homoscedasticity (Levene’s test) were tested. The results were expressed as means ± standard deviation (SD). Statistical significance was considered as P < 0.05.

Results

Prenatal hyperandrogenization on liver lipid content

Prenatal hyperandrogenization did not affect the hepatic TG content (Fig. 1a); however, FA levels (Fig. 1b) were increased in PHanov animals as compared with both PHiov and Control groups. On the other hand, the cholesterol content (Fig. 1c) was decreased in the PHiov phenotype, while cholesterol ester levels (Fig. 1d) were not altered in the PH groups as compared with the Control group.

Fig. 1. Liver lipid content at 90 days of age. (a) Triglycerides; (b) fatty acids; (c) cholesterol; (d) cholesterol esters. Each column represents the mean ± SD of Control and prenatally hyperandrogenized (PH) groups in six samples per group (a vs b P < 0.05, by ANOVA with post hoc Tukey test).

Prenatal hyperandrogenization on hepatic lipid mediators

The transcription factor involved in the FA synthesis regulation, PPARg, showed a lower expression in the PH phenotypes than in the Control group, in both mRNA (Fig. 2a) and protein levels (Fig. 2b). On the other hand, PPARa, a nuclear receptor isoform that regulates the FA oxidation pathways, presented no differences between groups in either mRNA (Fig. 3a) or protein levels (Fig. 3b).

Fig. 2. Effects of prenatal hyperandrogenism on PPARg expression. (a) mRNA abundance of Pparg relative to L32 mRNA levels of Control and prenatally hyperandrogenized (PH) groups, (b) results of Western Blot analysis for PPARg 1 + 2 corresponding to Control and PH groups. Each column represents the mean ± SD in six replicates per group (a vs b P < 0.01, by ANOVA with post hoc Tukey test).

Fig. 3. Effects of prenatal hyperandrogenism on PPARa expression. (a) mRNA abundance of Ppara relative to L32 mRNA levels of Control and prenatally hyperandrogenized (PH) groups, (b) results of Western Blot analysis for PPARa corresponding to Control and PH groups. Each column represents the mean ± SD in six replicates per group (P > 0.05, by ANOVA with post hoc Tukey test).

Prenatal hyperandrogenization on hepatic lipid metabolism

To study the hepatic lipid metabolism, we analyzed whether prenatal hyperandrogenization altered the mRNA levels of the main enzymes that participate in these pathways. The mRNA levels of Acaca and Acacb, the two isoforms of the ACC enzymes, did not present significant differences with respect to the Control group (Fig. 4a and 4b). However, Fas (Fig. 4c) and Scd1 (Fig. 4d) mRNA levels were increased in PHiov animals as compared with the PHanov and Control groups. In addition, regarding the Atgl mRNA levels, no significant differences were found between the PH and the Control groups (Fig. 4e). However, the Atgl mRNA levels of the PHiov phenotypes were increased when compared to those of the PHanov phenotype (Fig. 4e). Regarding the b-oxidation mediators, Pgc1a was not affected in the PH groups (Fig. 4f), but Cpt1 mRNA levels were increased in the PHiov phenotype as compared with the PHanov and Control groups (Fig. 4g).

Fig. 4. Effects of prenatal hyperandrogenism on the gene expression of liver lipid metabolism mediators. The graphs correspond to the mRNA abundance of the gene of interest relative to L32 mRNA levels of Control and prenatally hyperandrogenized (PH) groups. Gene expression of (a) Acaca, (b) Acacb, (c) Fas, (d) Scd1, (e) Atgl, (f) Pgc1a, and (g) Cpt1. Each column represents the mean ± SD in six replicates per group (a vs b P < 0.05, by ANOVA with post hoc Tukey test).

Prenatal hyperandrogenization on hepatic chemerin expression

We found that Chemerin mRNA levels did not show alterations in any of the phenotypes studied (Fig. 5a). However, CHEMERIN protein levels were decreased in the PHiov phenotype and were even lower in the PHanov phenotype as compared with the Control group (Fig. 5b).

Fig. 5. Effects of prenatal hyperandrogenism on hepatic chemerin. (a) mRNA abundance of Chemerin relative to L32 mRNA levels of Control and prenatally hyperandrogenized (PH) groups, (b) results of Western Blot analysis for CHEMERIN corresponding to Control and PH groups. Each column represents the mean ± SD in six replicates per group (a vs b vs c P < 0.01, by ANOVA with post hoc Tukey test).

Discussion

A hormonal imbalance, such as prenatal androgen excess, during the early stages of development can alter both endocrine and metabolic systems. Reference Fowden and Forhead44 Recently, there has been a great interest in studying hepatic functionality in androgenic contexts, since the regulation of lipid and glucose pathways in this organ was altered in hyperandrogenic PCOS women. Reference Vassilatou10 In our present research, we reproduced a murine model of prenatal hyperandrogenization which displayed PCOS-like features, Reference Heber, Ferreira and Abruzzese32,Reference Abruzzese, Heber and Campo Verde Arbocco45 leading to the development of two phenotypes from the same mother: PHiov and PHanov. Reference Abruzzese, Heber and Ferreira27

The liver is an essential organ involved in the regulation of energy homeostasis. Reference Rui46 It expresses sex steroid receptors, and both androgens and estrogens have direct as well as indirect effects on hepatic function. Reference Shen and Shi47 Besides, sex steroids have been implicated in the transcriptional regulation of several hepatic genes that play key roles in lipid metabolism. Reference Grossmann, Wierman and Angus48 In that sense, in previous studies, we demonstrated that prenatal hyperandrogenization alters female hepatic functions and lipogenesis at pubertal stage. Reference Abruzzese, Heber and Ferreira27 However, there was no evidence of TG accumulation neither at puberty nor at adulthood. Reference Abruzzese, Heber and Ferrer26,Reference Abruzzese, Heber and Ferreira27 Moreover, we found that the lipid content and a key metabolism mediator, PPARg, varied at different stages in the ovary. Reference Heber, Ferreira and Vélez28 Thereby, prenatal hyperandrogenization induces alterations in lipid metabolism that may change throughout life. Taken together, these considerations led us to deepen the study of hepatic lipid pathways on adulthood and analyze the reach of prenatal androgen exposure on the lipid content considering different lipid species.

We confirmed that there is no TG accumulation in the liver of PH animals. Contrary to other reports, Reference Demissie, Lazic and Foecking30,Reference Grossmann, Wierman and Angus48 in which prenatally androgenized offspring that were fed with a high-fat diet exhibited significantly increased body weight and hepatic TG content, in our work, the animals were not subjected to a high-fat diet. In this regard, it was demonstrated that a high-fat diet increased the liver TG content considerably, both in control and PH rats. Reference Demissie, Lazic and Foecking30 Then, the regular feeding could have contributed to maintaining a normal weight, as we previously reported. Reference Abruzzese, Heber and Ferrer26 Additionally, it is important to consider that the studies performed with prenatal androgen exposure that showed hepatic TG accumulation presented differences in the strain and testosterone dose.9,Reference Demissie, Lazic and Foecking30,Reference Lazic, Aird and Levine49 Such differences could account for those controversial results.

Despite the TG content was not impaired in the PH group, the FA levels did present alterations both in their hepatic amount and in the enzymes involved in their synthesis and regulation (Fig. 6). In the FA metabolism, control participates two important transcription factors: PPARg, which is involved in the regulation of the enzymes that participate in FA synthesis, Reference Ables16 and PPARa, which regulates the enzymes involved in FA oxidation. Reference Pawlak, Lefebvre and Staels15 We found that the mRNA levels of Pparg were decreased in PH animals. These data are in agreement with our previous findings, Reference Abruzzese, Heber and Ferrer26 and in this work, we also found that PPARg protein levels are consistent with the mRNA levels, thus showing a dysregulation of this transcriptional factor. Moreover, considering that a liver deficiency of PPARg worsens the hyperglycemia and the systemic insulin resistance, Reference Matsusue, Haluzik and Lambert50,Reference Wang, Nakajima and Gonzalez51 these results contribute to the understanding of the altered metabolic state that we have previously reported. Reference Abruzzese, Heber and Ferrer26 Taken together these findings, prenatal hyperandrogenization induces alterations in PPARg expression, contributing to disruptions in lipid homeostasis. On the other hand, we found no alterations in either the mRNA or protein levels of PPARa in any of the groups studied. Considering that this transcriptional factor is the master regulator of FA oxidation, Reference Rui46 the result might indicate that the nuclear receptor does not affect the FA oxidation pathways. However, PPARs bind to DNA in a PPAR response element (PPRE) as a heterodimer containing PPARa and retinoic X receptor alpha. The heterodimer acts as ligand-activated transcription factor, affecting the interactions with co-activators or co-repressors to stimulate or inhibit its functions. Reference Pawlak, Lefebvre and Staels15,Reference Bougarne, Weyers and Desmet52 Thus, failures in the heterodimer interactions with co-activators or co-repressors or in the binding of the PPAR to DNA could alter PPARa-dependent gene regulation. Reference Pawlak, Baugé and Bourguet53 In fact, previous studies have demonstrated that a nuclear receptor co-activator is essential in PPARa functionality, Reference Pawlak, Lefebvre and Staels15 and that a PPARa-driven activation depends on PPRE binding in vitro and in vivo in a PPARa-deficient mice model. Reference Pawlak, Baugé and Bourguet53 Moreover, since polyunsaturated FAs are endogenous ligands of PPARa, Reference Contreras, Torres and Tovar54 changes in the concentration of these lipids directly impact on the PPARa activity. Thereby, although we found no variation in PPARa expression, its activity may be impaired. Then, further studies are needed to clarify this point.

Fig. 6. Liver lipid metabolism studied in this work. The different steps of the metabolic pathways are linked by thin black arrows. The dotted thin black arrows represent the presence of multiple intermediate steps. The results obtained in this work are showed as follows: wide solid arrows indicate dysregulation in PH phenotypes (increased or decreased levels) with respect to the Control group. Wide striped arrows indicate tendency without significant statistical differences with respect to the Control group. Equal sings indicate no alterations with respect to the Control group. PHiov phenotype is represented in grey and PHanov in black. Concerning chemerin, the results of the mRNA levels are indicated first, and the protein levels are indicated second, following the phenotype colors previously mentioned. ACC, acetyl-CoA carboxylase; ATGL, adipose triglyceride lipase; CPT1, carnitine palmitoyltransferase 1; FA, fatty acids; FAS, fatty acid synthase; PGC1a, PPAR co-activator 1a; PPARa, peroxisomal proliferator-activated receptor alpha; PPARg, peroxisomal proliferator-activated receptor gamma; SCD1, stearoyl-CoA desaturase 1.

To further analyze FA metabolism, we evaluated the expression of key enzymes of lipogenesis and FA oxidation (Fig. 6). The FA synthesis starts with acetyl-CoA, which is used to get malonyl-CoA by ACC, an enzyme that presents two isoforms: ACC1 and ACC2, encoded by the Acaca and Acacb genes, respectively. Surprisingly, our results showed that the mRNA levels of both isoforms were not affected in the PH phenotypes, although high levels of FA content in the PHanov phenotype and decreased levels of PPARg were obtained in both PH phenotypes. In that sense, since the synthesis of malonyl-CoA is a crucial step in lipid metabolism, as it determinates whether FAs are synthesized or oxidized, the ACC enzymes are highly controlled Reference Strable and Ntambi55 and, although PPARg is a master regulator of ACC, other factors that could be influencing the lipogenic enzymes expression must be considered. ACC expression depends on a variety of factors including glucose, insulin, thyroid hormone, catabolic hormones, and leptin. Reference Brownsey, Boone and Elliott56 Among the key transcription factors that regulate the ACC gene expression, it has been demonstrated that Liver X receptors is important not only in the regulation of FA synthesis but also in mediating the glucose and insulin response of other transcription factors. Reference Strable and Ntambi55

To deepen the study of the lipogenic genes, we analyzed the mRNA levels of the genes encoding FAS and SCD1, both enzymes involved in lipogenesis. We found higher mRNA levels of Fas and Scd1 in the PHiov phenotype than in the Control group. These enzymes catalyze rate-limiting steps in the synthesis of FA. Reference Strable and Ntambi55 Fas utilizes malonyl-CoA as substrate, which inhibits CPT1. Thus, the high Fas mRNA levels seem to favor the FA oxidation, as the enzyme removes the malonyl-CoA and the transporter could act without any inhibition. Reference Strable and Ntambi55 In fact, high mRNA levels of Cpt1, which mediates the acyl-CoA translocation into the mitochondria, were found. Thereby, the transporter is enabling the FA availability for oxidation. Moreover, high hepatic SCD1 activity has been associated with the prevention of liver fat accumulation, Reference Silbernagel, Kovarova and Cegan57 consistent with the unaffected hepatic TG content. Since, no differences were found in the FA amounts in the PHiov group, this phenotype seems to present a balance between these two lipid species.

TGs are hydrolyzed mainly by ATGL to release FA and diacylglycerol Reference Rui46 (Fig. 6). We found that Atgl mRNA levels showed a tendency to increase in the PHiov phenotype and a tendency to decrease in the PHanov phenotype, although without significant statistical differences with respect to the Control group. However, we did observe differences in Atgl mRNA levels between the two PH phenotypes, being higher in the PHiov than in the PHanov phenotype. The increased Atgl mRNA levels in the PHiov phenotype could be contributing to the balance between the FA and TG content that was mentioned above. However, an increased level of FA was observed in the PHanov group. In this regard, we have previously found disturbances in the hepatic glucose and insulin signaling. Reference Abruzzese, Heber and Ferrer26 In the liver, glucose transport is carried out by GLUT2, Reference Nordlie, Foster and Lange58 and, in previously findings, we obtained a decrease in the gene expression of glut2 in both PH groups. Reference Abruzzese, Heber and Ferrer26 Moreover, it has been demonstrated that GLUT2 can be a direct target of PPARg. Reference Kim and Ahn59 We have shown in this work that PPARg, which plays an important role in glucose homeostasis, Reference Kallwitz, McLachlan and Cotler60 presented decreased mRNA and protein levels in both PH phenotypes. Then, our results agree with the low gene expression of the glucose transporter. Considering that these alterations impair the liver glucose uptake, Reference White61,Reference Rencurel, Waeber and Antoine62 and that the mRNA levels of the limited enzymes that participate in de novo lipogenesis are not affected, the high FA levels in the PHanov phenotype could be due to the entrance of this lipid species from circulation to the liver, Reference Kawano and Cohen5 as a compensated pathway to the glucose deficiency. Nevertheless, further studies are needed to elucidate this aspect. Since no TG accumulation was found, the balance between the high FA levels and their oxidation may explain the results. Reference Rui46,Reference White61 Actually, when analyzing the status of FA oxidation, we found that the expression of Pgc1a and Ppara was not altered. PGC1a not only acts as a PPARa co-activator but also modulates mitochondrial functions and glucose homeostasis. Reference Liang and Ward63,Reference Fernandez-Marcos and Auwerx64 Taken together these data, both master regulators are facilitating the b-oxidation.

It has been reported that in a hyperandrogenic state, the cholesterol efflux capacity, in which this lipid removal from peripheral tissues is delivered to the liver, is reduced. Reference Roe, Hillman and Butts65 In that sense, when evaluating the cholesterol content, it showed a decreased level in PHiov animals and a tendency to decrease in the PHanov group. These data are in agreement with those previous findings. Reference Roe, Hillman and Butts65 Moreover, cholesterol is a potential lipotoxic molecule that causes cellular toxicity or acts in a pro-inflammatory or pro-fibrotic manner. Reference Ioannou66 One strategy for the cells to avoid cholesterol accumulation is its esterification, resulting in cholesterol esters. Reference Chen, Chen and Huang67 In this work, we found no alterations in cholesterol ester levels between groups. Since there is no evidence of hepatic damage at adulthood in our animal model, as we have previously demonstrated, Reference Abruzzese, Heber and Ferrer26 our results are consistent with these findings.

Finally, we assessed the status of chemerin in the liver (Fig. 6). It is an adipokine associated with obesity, NAFLD, and metabolic syndrome, participating in glucose homeostasis and inflammatory processes. Reference Bozaoglu, Bolton and McMillan21,Reference Goralski, McCarthy and Hanniman68 In this work, we found that the liver mRNA levels of this adipokine showed no alterations between Controls and PH animals. Nevertheless, CHEMERIN protein levels were decreased in the PHiov phenotype and even lower in the PHanov phenotype. Despite the fact that PPARg has been described to regulate Chemerin mRNA levels in different tissues such as adipose tissue and ovary, Reference Muruganandan, Parlee and Rourke17,Reference Mishra, Bharati and Bharti69 here, we found that the hepatic mRNA levels of Chemerin are not concordant with those obtained for PPARg. This could be due to a tissue-specific PPARg action as a transcription factor. In that sense, other results have demonstrated that PPARg activation increased chemerin expression in white adipose tissue but not liver. Reference Muruganandan, Parlee and Rourke17,Reference Goralski, McCarthy and Hanniman68 Thus, further studies are needed to determine whether PPARg action actually regulates chemerin expression in the liver in androgenic conditions. Moreover, we found an inconsistency between chemerin mRNA and protein levels. This difference between the gene and protein expression may be explained due to the post-transcriptional and post-translational mechanisms that regulate the processing of mRNAs and proteins. Reference Mattern, Zellmann and Beck-Sickinger70

Although the role of chemerin in the systemic metabolism is not yet clear, it has been shown that this adipokine affects insulin sensitivity, as it has been demonstrated in a chemerin knockout model. Reference Helfer and Wu25 However, these results for either hepatic or serum concentrations are controversial, Reference Horn, von Loeffelholz and Forkert71,Reference Alfadda, Sallam and Chishti72 and more research is needed. The results so far suggest that changes in this adipokine levels reveal signs of alterations in liver functionality. Reference Helfer and Wu25 Furthermore, it has been shown a positive correlation between chemerin concentration and lipid content in the liver. Reference Kłusek-Oksiuta, Bialokoz-Kalinowska and Tarasów73

In summary, we found that prenatal hyperandrogenization alters the liver lipid content. We also found a disturbance of FA metabolism mediated by PPARg as well as an imbalance of the mRNA levels of the lipid metabolism enzymes. Finally, we showed an alteration in the protein expression of CHEMERIN, indicating a liver dysfunction resulting from the androgen exposure during fetal development. In that sense, these results highlight the link between androgen actions and hepatic lipid metabolism. However, further studies are needed to elucidate the role of this sex steroid hormone in the pathogenesis of metabolic liver disease.

Acknowledgements

We thank Enzo Cuba and Marcela Marquez for their technical support in the animal care.

Financial support

This study was supported by grants from Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT) (Grant PICT 632/2016), Fundación Alberto Roemmers, Argentina, and Universidad de Buenos Aires (20720160100004BA/2017).

Conflicts of interest

The authors have no conflicts of interest to declare.

Ethical standards

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national guides on the care and use of laboratory animals committee of Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) 1996, Argentina, and the study was approved by the Ethics Committee of the School of Medicine of University of Buenos Aires, Argentina.

References

Marciniak, A, Patro-Małysza, J, Kimber-Trojnar, Ż, et al. Fetal programming of the metabolic syndrome. Taiwan J Obstet Gynecol. 2017; 56, 133138.10.1016/j.tjog.2017.01.001CrossRefGoogle ScholarPubMed
Saffery, R, Novakovic, B. Epigenetics as the mediator of fetal programming of adult onset disease: what is the evidence? Acta Obstet Gynecol Scand. 2014; 93, 10901098.10.1111/aogs.12431CrossRefGoogle ScholarPubMed
Trefts, E, Gannon, M, Wasserman, DH. The liver. Curr Biol. 2017; 27, R1147R1151.10.1016/j.cub.2017.09.019CrossRefGoogle ScholarPubMed
Paschos, P, Paletas, K. Non-alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009; 13, 919.Google ScholarPubMed
Kawano, Y, Cohen, DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013; 48, 434441.10.1007/s00535-013-0758-5CrossRefGoogle ScholarPubMed
Ma, W-L, Lai, H-C, Yeh, S, et al. Androgen receptor roles in hepatocellular carcinoma, cirrhosis, and hepatitis. Endocr Relat Cancer. 2014; 21, R165R182.10.1530/ERC-13-0283CrossRefGoogle ScholarPubMed
Marchesini, G, Brizi, M, Morselli-Labate, AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999; 107, 450455.10.1016/S0002-9343(99)00271-5CrossRefGoogle ScholarPubMed
Diamanti-Kandarakis, E, Dunaif, A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012; 33, 9811030.10.1210/er.2011-1034CrossRefGoogle ScholarPubMed
Sun, M, Maliqueo, M, Benrick, A, et al. Maternal androgen excess reduce placental and fetal weights, increase placental steroidogenesis and leads to long-term health effects in their female offspring. Am J Physiol Endocrinol Metab. 303. Epub ahead of print 9 October 2012. doi: 10.1152/ajpendo.00421.2012.CrossRefGoogle Scholar
Vassilatou, E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol. 2014; 20, 83518363.10.3748/wjg.v20.i26.8351CrossRefGoogle ScholarPubMed
Browning, JD, Horton, JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004; 114, 147152.10.1172/JCI200422422CrossRefGoogle ScholarPubMed
Nguyen, P, Leray, V, Diez, M, et al. Liver lipid metabolism. J Anim Physiol Anim Nutr. 2008; 92, 272283.10.1111/j.1439-0396.2007.00752.xCrossRefGoogle ScholarPubMed
Smith, SA. Peroxisome proliferator-activated receptors and the regulation of mammalian lipid metabolism. Biochem Soc Trans. 2002; 30, 10861090.10.1042/bst0301086CrossRefGoogle ScholarPubMed
Tyagi, S, Gupta, P, Saini, AS, et al. The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2011; 2, 236240.10.4103/2231-4040.90879CrossRefGoogle ScholarPubMed
Pawlak, M, Lefebvre, P, Staels, B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015; 62, 720733.10.1016/j.jhep.2014.10.039CrossRefGoogle ScholarPubMed
Ables, GP. Update on PPARγ and nonalcoholic fatty liver disease. PPAR Res. 2012; 2012, 912351.10.1155/2012/912351CrossRefGoogle ScholarPubMed
Muruganandan, S, Parlee, SD, Rourke, JL, et al. Chemerin, a novel peroxisome proliferator-activated receptor γ (PPARγ) target gene that promotes mesenchymal stem cell adipogenesis. J Biol Chem. 2011; 286, 2398223995.10.1074/jbc.M111.220491CrossRefGoogle ScholarPubMed
Boutari, C, Perakakis, N, Mantzoros, CS. Association of adipokines with development and progression of nonalcoholic fatty liver disease. Endocrinol Metab. 2018; 33, 3343.10.3803/EnM.2018.33.1.33CrossRefGoogle ScholarPubMed
Lago, F, Gómez, R, Gómez-Reino, JJ, et al. Adipokines as novel modulators of lipid metabolism. Trends Biochem Sci. 2009; 34, 500510.10.1016/j.tibs.2009.06.008CrossRefGoogle ScholarPubMed
Polyzos, SA, Kountouras, J, Mantzoros, CS. Adipokines in nonalcoholic fatty liver disease. Metabolism. 2016; 65, 10621079.10.1016/j.metabol.2015.11.006CrossRefGoogle ScholarPubMed
Bozaoglu, K, Bolton, K, McMillan, J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007; 148, 46874694.10.1210/en.2007-0175CrossRefGoogle ScholarPubMed
Ademoglu, E, Berberoglu, Z, Carlioglu, A, et al. Higher levels of circulating chemerin in both lean and obese patients with polycystic ovary syndrome. Minerva Ginecol. 2014; 66, 535542.Google ScholarPubMed
Ferland, DJ, Watts, SW. Chemerin: a comprehensive review elucidating the need for cardiovascular research. Pharmacol Res. 2015; 99, 351361.10.1016/j.phrs.2015.07.018CrossRefGoogle ScholarPubMed
Bondue, B, Wittamer, V, Parmentier, M. Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev. 2011; 22, 331338.10.1016/j.cytogfr.2011.11.004CrossRefGoogle ScholarPubMed
Helfer, G, Wu, Q-F. Chemerin: a multifaceted adipokine involved in metabolic disorders. J Endocrinol. 2018; 238, R79R94.10.1530/JOE-18-0174CrossRefGoogle ScholarPubMed
Abruzzese, GA, Heber, MF, Ferrer, MJ, et al. Effects of in utero androgen excess and metformin treatment on hepatic functions. Mol Cell Endocrinol. 2019; 491, 110416.10.1016/j.mce.2019.03.006CrossRefGoogle ScholarPubMed
Abruzzese, GA, Heber, MF, Ferreira, SR, et al. Prenatal hyperandrogenism induces alterations that affect liver lipid metabolism. J Endocrinol. 2016; 230, 6779.10.1530/JOE-15-0471CrossRefGoogle ScholarPubMed
Heber, MF, Ferreira, SR, Vélez, LM, et al. Prenatal hyperandrogenism and lipid profile during different age stages: an experimental study. Fertil Steril. 2013; 99, 551557.10.1016/j.fertnstert.2012.10.017CrossRefGoogle ScholarPubMed
Padmanabhan, V, Salvetti, NR, Matiller, V, et al. Developmental programming: prenatal steroid excess disrupts key members of intraovarian steroidogenic pathway in sheep. Endocrinology. 2014; 155, 36493660.10.1210/en.2014-1266CrossRefGoogle ScholarPubMed
Demissie, M, Lazic, M, Foecking, EM, et al. Transient prenatal androgen exposure produces metabolic syndrome in adult female rats. Am J Physiol-Endocrinol Metab. 2008; 295, E262E268.10.1152/ajpendo.90208.2008CrossRefGoogle ScholarPubMed
Wolf, CJ, Hotchkiss, A, Ostby, JS, et al. Effects of prenatal testosterone propionate on the sexual development of male and female rats: a dose-response study. Toxicol Sci Off J Soc Toxicol. 2002; 65, 7186.10.1093/toxsci/65.1.71CrossRefGoogle ScholarPubMed
Heber, MF, Ferreira, SR, Abruzzese, GA, et al. Metformin improves ovarian insulin signaling alterations caused by fetal programming. J Endocrinol. Epub ahead of print 1 January 2019. doi: 10.1530/JOE-18-0520.CrossRefGoogle Scholar
Chow, JDY, Jones, MEE, Prelle, K, et al. A selective estrogen receptor α agonist ameliorates hepatic steatosis in the male aromatase knockout mouse. J Endocrinol. 2011; 210, 323334.10.1530/JOE-10-0462CrossRefGoogle ScholarPubMed
Bligh, EG, Dyer, WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37, 911917.10.1139/y59-099CrossRefGoogle ScholarPubMed
Bradford, MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72, 248254.10.1016/0003-2697(76)90527-3CrossRefGoogle ScholarPubMed
Fornes, D, White, V, Higa, R, et al. Sex-dependent changes in lipid metabolism, PPAR pathways and microRNAs that target PPARs in the fetal liver of rats with gestational diabetes. Mol Cell Endocrinol. 2018; 461, 1221.10.1016/j.mce.2017.08.004CrossRefGoogle ScholarPubMed
Livak, KJ, Schmittgen, TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods San Diego Calif. 2001; 25, 402408.CrossRefGoogle Scholar
Araujo, LCC, Bordin, S, Carvalho, CRO. Reference gene and protein expression levels in two different NAFLD mouse models. Gastroenterol Res Pract. 2020. Epub ahead of print 3 February 2020. doi: 10.1155/2020/1093235.CrossRefGoogle Scholar
Rein-Fischboeck, L, Pohl, R, Haberl, EM, et al. Tubulin alpha 8 is expressed in hepatic stellate cells and is induced in transformed hepatocytes. Mol Cell Biochem. 2017; 428, 161170.10.1007/s11010-016-2926-4CrossRefGoogle ScholarPubMed
Moritz, CP. Tubulin or not tubulin: heading toward total protein staining as loading control in western blots. Proteomics. 17. Epub ahead of print October 2017. doi: 10.1002/pmic.201600189.CrossRefGoogle Scholar
Collins, MA, An, J, Peller, D, et al. Total protein is an effective loading control for cerebrospinal fluid western blots. J Neurosci Methods. 2015; 251, 7282.CrossRefGoogle ScholarPubMed
Nie, X, Li, C, Hu, S, et al. An appropriate loading control for western blot analysis in animal models of myocardial ischemic infarction. Biochem Biophys Rep. 2017; 12, 108113.Google ScholarPubMed
Di Rienzo, J, Casanoves, F, Balzarini, M, et al. InfoStat Versión 2011. https://www.infostat.com.ar/index.php.Google Scholar
Fowden, AL, Forhead, AJ. Endocrine mechanisms of intrauterine programming. Reprod Camb Engl. 2004; 127, 515526.Google ScholarPubMed
Abruzzese, GA, Heber, MF, Campo Verde Arbocco, F, et al. Fetal programming by androgen excess in rats affects ovarian fuel sensors and steroidogenesis. J Dev Orig Health Dis. 2019; 10, 114.10.1017/S2040174419000126CrossRefGoogle ScholarPubMed
Rui, L. Energy metabolism in the liver. Compr Physiol. 2014; 4, 177197.10.1002/cphy.c130024CrossRefGoogle ScholarPubMed
Shen, M, Shi, H. Sex hormones and their receptors regulate liver energy homeostasis. Int J Endocrinol. 2015. Epub ahead of print 2015. doi: 10.1155/2015/294278.CrossRefGoogle Scholar
Grossmann, M, Wierman, ME, Angus, P, et al. Reproductive endocrinology of nonalcoholic fatty liver disease. Endocr Rev. 2019; 40, 417446.10.1210/er.2018-00158CrossRefGoogle ScholarPubMed
Lazic, M, Aird, F, Levine, JE, et al. Prenatal androgen treatment alters body composition and glucose homeostasis in male rats. J Endocrinol. 2011; 208, 293300.Google ScholarPubMed
Matsusue, K, Haluzik, M, Lambert, G, et al. Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest. 2003; 111, 737747.10.1172/JCI200317223CrossRefGoogle ScholarPubMed
Wang, Y, Nakajima, T, Gonzalez, FJ, et al. PPARs as metabolic regulators in the liver: lessons from liver-specific PPAR-null mice. Int J Mol Sci. 21. Epub ahead of print 17 March 2020. doi: 10.3390/ijms21062061.CrossRefGoogle Scholar
Bougarne, N, Weyers, B, Desmet, SJ, et al. Molecular actions of PPARα in lipid metabolism and inflammation. Endocr Rev. 2018; 39, 760802.10.1210/er.2018-00064CrossRefGoogle ScholarPubMed
Pawlak, M, Baugé, E, Bourguet, W, et al. The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice. Hepatology. 2014; 60, 15931606.10.1002/hep.27297CrossRefGoogle ScholarPubMed
Contreras, AV, Torres, N, Tovar, AR. PPAR-α as a key nutritional and environmental sensor for metabolic adaptation12. Adv Nutr. 2013; 4, 439452.10.3945/an.113.003798CrossRefGoogle Scholar
Strable, MS, Ntambi, JM. Genetic control of de novo lipogenesis: role in diet-induced obesity. Crit Rev Biochem Mol Biol. 2010; 45, 199214.10.3109/10409231003667500CrossRefGoogle ScholarPubMed
Brownsey, RW, Boone, AN, Elliott, JE, et al. Regulation of acetyl-CoA carboxylase. Biochem Soc Trans. 2006; 34, 223227.10.1042/BST0340223CrossRefGoogle ScholarPubMed
Silbernagel, G, Kovarova, M, Cegan, A, et al. High hepatic SCD1 activity is associated with low liver fat content in healthy subjects under a lipogenic diet. J Clin Endocrinol Metab. 2012; 97, E2288E2292.CrossRefGoogle Scholar
Nordlie, RC, Foster, JD, Lange, AJ. Regulation of glucose production by the liver. Annu Rev Nutr. 1999; 19, 379406.CrossRefGoogle ScholarPubMed
Kim, H, Ahn, Y. Role of peroxisome proliferator-activated receptor-γ in the glucose-sensing apparatus of liver and β-cells. Diabetes. 2004; 53, S60S65.10.2337/diabetes.53.2007.S60CrossRefGoogle ScholarPubMed
Kallwitz, ER, McLachlan, A, Cotler, SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol. 2008; 14, 2228.CrossRefGoogle ScholarPubMed
White, MF. IRS proteins and the common path to diabetes. Am J Physiol-Endocrinol Metab. 2002; 283, E413E422.CrossRefGoogle ScholarPubMed
Rencurel, F, Waeber, G, Antoine, B, et al. Requirement of glucose metabolism for regulation of glucose transporter type 2 (GLUT2) gene expression in liver. Biochem J. 1996; 314, 903909.10.1042/bj3140903CrossRefGoogle ScholarPubMed
Liang, H, Ward, WF. PGC-1α: a key regulator of energy metabolism. Adv Physiol Educ. 2006; 30, 145151.CrossRefGoogle ScholarPubMed
Fernandez-Marcos, PJ, Auwerx, J. Regulation of PGC-1α, a nodal regulator of mitochondrial biogenesis1234. Am J Clin Nutr. 2011; 93, 884S890S.CrossRefGoogle Scholar
Roe, A, Hillman, J, Butts, S, et al. Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS. J Clin Endocrinol Metab. 2014; 99, E841E847.CrossRefGoogle ScholarPubMed
Ioannou, GN. The role of cholesterol in the pathogenesis of NASH. Trends Endocrinol Metab. 2016; 27, 8495.Google Scholar
Chen, L, Chen, X-W, Huang, X, et al. Regulation of glucose and lipid metabolism in health and disease. Sci China Life Sci. 2019; 62, 14201458.CrossRefGoogle ScholarPubMed
Goralski, KB, McCarthy, TC, Hanniman, EA, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007; 282, 2817528188.CrossRefGoogle ScholarPubMed
Mishra, S, Bharati, J, Bharti, M, et al. Adipokines as metabolic modulators of ovarian functions in livestock: a mini-review. J Adv Vet Anim Res. 2016; 3, 206.CrossRefGoogle Scholar
Mattern, A, Zellmann, T, Beck-Sickinger, AG. Processing, signaling, and physiological function of chemerin. IUBMB Life. 2014; 66, 1926.CrossRefGoogle ScholarPubMed
Horn, P, von Loeffelholz, C, Forkert, F, et al. Low circulating chemerin levels correlate with hepatic dysfunction and increased mortality in decompensated liver cirrhosis. Sci Rep. 8. Epub ahead of print 18 June 2018. doi: 10.1038/s41598-018-27543-6.CrossRefGoogle Scholar
Alfadda, AA, Sallam, RM, Chishti, MA, et al. Differential patterns of serum concentration and adipose tissue expression of chemerin in obesity: adipose depot specificity and gender dimorphism. Mol Cells. 2012; 33, 591596.CrossRefGoogle ScholarPubMed
Kłusek-Oksiuta, M, Bialokoz-Kalinowska, I, Tarasów, E, et al. Chemerin as a novel non-invasive serum marker of intrahepatic lipid content in obese children. Ital J Pediatr. 40. Epub ahead of print 17 November 2014. doi: 10.1186/s13052-014-0084-4.CrossRefGoogle Scholar
Figure 0

Table 1. List of primers used in real-time PCR

Figure 1

Fig. 1. Liver lipid content at 90 days of age. (a) Triglycerides; (b) fatty acids; (c) cholesterol; (d) cholesterol esters. Each column represents the mean ± SD of Control and prenatally hyperandrogenized (PH) groups in six samples per group (a vs b P < 0.05, by ANOVA with post hoc Tukey test).

Figure 2

Fig. 2. Effects of prenatal hyperandrogenism on PPARg expression. (a) mRNA abundance of Pparg relative to L32 mRNA levels of Control and prenatally hyperandrogenized (PH) groups, (b) results of Western Blot analysis for PPARg 1 + 2 corresponding to Control and PH groups. Each column represents the mean ± SD in six replicates per group (a vs b P < 0.01, by ANOVA with post hoc Tukey test).

Figure 3

Fig. 3. Effects of prenatal hyperandrogenism on PPARa expression. (a) mRNA abundance of Ppara relative to L32 mRNA levels of Control and prenatally hyperandrogenized (PH) groups, (b) results of Western Blot analysis for PPARa corresponding to Control and PH groups. Each column represents the mean ± SD in six replicates per group (P > 0.05, by ANOVA with post hoc Tukey test).

Figure 4

Fig. 4. Effects of prenatal hyperandrogenism on the gene expression of liver lipid metabolism mediators. The graphs correspond to the mRNA abundance of the gene of interest relative to L32 mRNA levels of Control and prenatally hyperandrogenized (PH) groups. Gene expression of (a) Acaca, (b) Acacb, (c) Fas, (d) Scd1, (e) Atgl, (f) Pgc1a, and (g) Cpt1. Each column represents the mean ± SD in six replicates per group (a vs b P < 0.05, by ANOVA with post hoc Tukey test).

Figure 5

Fig. 5. Effects of prenatal hyperandrogenism on hepatic chemerin. (a) mRNA abundance of Chemerin relative to L32 mRNA levels of Control and prenatally hyperandrogenized (PH) groups, (b) results of Western Blot analysis for CHEMERIN corresponding to Control and PH groups. Each column represents the mean ± SD in six replicates per group (a vs b vs c P < 0.01, by ANOVA with post hoc Tukey test).

Figure 6

Fig. 6. Liver lipid metabolism studied in this work. The different steps of the metabolic pathways are linked by thin black arrows. The dotted thin black arrows represent the presence of multiple intermediate steps. The results obtained in this work are showed as follows: wide solid arrows indicate dysregulation in PH phenotypes (increased or decreased levels) with respect to the Control group. Wide striped arrows indicate tendency without significant statistical differences with respect to the Control group. Equal sings indicate no alterations with respect to the Control group. PHiov phenotype is represented in grey and PHanov in black. Concerning chemerin, the results of the mRNA levels are indicated first, and the protein levels are indicated second, following the phenotype colors previously mentioned. ACC, acetyl-CoA carboxylase; ATGL, adipose triglyceride lipase; CPT1, carnitine palmitoyltransferase 1; FA, fatty acids; FAS, fatty acid synthase; PGC1a, PPAR co-activator 1a; PPARa, peroxisomal proliferator-activated receptor alpha; PPARg, peroxisomal proliferator-activated receptor gamma; SCD1, stearoyl-CoA desaturase 1.